VIP — a peptide studied for immune modulation, neurological function, and inflammatory airway conditions.
Also known as: Vasoactive Intestinal Peptide
Vasoactive Intestinal Peptide, or VIP, is a 28-amino-acid neuropeptide originally isolated from the intestinal tract but later found throughout the central and peripheral nervous systems and in cells of the immune system. It belongs to a family of regulatory peptides that includes glucagon, secretin, and growth hormone-releasing hormone, and it acts as a neurotransmitter, hormone, and immune signaling molecule depending on where in the body it's released.
What makes VIP unusual among peptides is the breadth of systems it touches. It influences brain activity, neuroendocrine function, breathing, digestion, blood flow, and immune cell behavior — all through a shared family of receptors (VPAC1, VPAC2, and PAC1) that trigger intracellular signaling primarily through cyclic AMP. Researchers have studied it as a potential tool for allergic airway disease, cognitive decline, and inflammatory conditions where the body's signaling between nerves and immune cells appears to go awry.
VIP is rapidly degraded in circulation, which has driven significant work into stable analogues and targeted delivery systems designed to extend its half-life and direct it to specific tissues.
2 vendors carry VIP.
Compare prices →Asthma and related allergic airway conditions are among the most actively studied applications for VIP. The peptide appears to dampen the immune cascade that drives allergic inflammation — particularly the Th2-type response involving eosinophils (a class of white blood cell central to allergic reactions) and the cytokines IL-4, IL-5, and IL-13 that recruit and activate them.
A 2023 study testing VIP in an asthma model found that treatment reduced eosinophil counts, IgE antibody levels, and the inflammatory cytokines IL-4, IL-5, and IL-13, while also lowering oxidative stress markers and reducing mucus overproduction in the airways (1). The same study tested a targeted delivery system pairing VIP with an adhesion protein and alpha-alumina carrier; this combination penetrated airway mucus more effectively and produced stronger, longer-lasting effects than VIP alone (1).
The broader rationale for VIP in allergic disease comes from its receptor distribution. VPAC1, VPAC2, CRTH2, and PAC1 receptors are all present on eosinophils, mast cells, neutrophils, and lymphocytes — the cell types that drive asthma, allergic rhinitis, and atopic dermatitis (3). Because VIP can engage these receptors directly, it appears to act as a brake on the inflammatory cells already gathered at the site of an allergic response. Reviewers have proposed that stable VIP analogues could become a useful direction for treating these conditions, since native VIP degrades too quickly for practical clinical use (3).
In the brain, VIP functions as a neurotransmitter and neuromodulator, with a particular concentration in the cerebral cortex and hippocampus. Cortical VIP neurons are bipolar cells that arborize within tight columns of 60 to 100 micrometers, positioning them to coordinate small, defined patches of brain tissue (9). They appear to link three things at once: neuronal firing, local blood flow, and energy metabolism — VIP stimulates cyclic AMP formation in both cerebral microvessels and astrocytes (the support cells of the brain), and it promotes glycogen breakdown in astrocytes to release fuel for nearby neurons (9).
In the hippocampus — the brain region central to learning and memory — VIP modulates synaptic plasticity, the cellular process underlying memory formation. It regulates GABAergic transmission (the brain's main inhibitory signaling system) and influences both long-term potentiation (LTP) and long-term depression (LTD), the two opposing processes that strengthen or weaken synaptic connections during learning (2). VPAC1 and VPAC2 receptors mediate distinct effects on pyramidal cell excitability, and reviewers have proposed selective VIP receptor ligands as therapeutic targets for cognitive decline and mesial temporal lobe epilepsy with hippocampal sclerosis (2).
VIP also acts as a neuronal survival factor during development. Studies have found that it stimulates the proliferation and differentiation of brain neurons, increases survival in spinal cord cultures, and triggers astroglial cells to secrete activity-dependent neurotrophic factor (ADNF) (4, 7).
VIP sits at the intersection of the nervous system and the immune system. VIP-containing nerves run directly into lymphoid organs, in close anatomical contact with immune effector cells, and high-affinity VIP receptors are present on lymphocytes themselves — meaning VIP can signal to immune cells both as a circulating peptide and as a locally released neurotransmitter (6). Some immune cells produce their own VIP, suggesting an autocrine signaling loop where the peptide regulates its own producer cells (6).
Functionally, VIP appears to influence T-cell recognition, antibody production, and the maturation and homing of immune effector cells. Most of these effects work through cyclic AMP generation inside the target cell, which then triggers downstream changes in cell behavior (6). The net direction of VIP's influence is generally protective and anti-inflammatory — researchers have noted that loss of VIP-containing nerves in inflammatory bowel disease and asthma appears to worsen the inflammatory response, suggesting the intact peptide normally restrains it (6).
The peptide's effects are highly context-dependent: the same VIP signal can produce different outcomes depending on which immune cells are present, what cytokines are already in the microenvironment, and the activation state of the target cell. This complexity is why developing stable VIP-like compounds for clinical use has been a long-running research goal rather than a quick translation.
VIP works through a family of G-protein-coupled receptors — VPAC1, VPAC2, and PAC1 — that primarily signal by elevating intracellular cyclic AMP, a universal second messenger that triggers a cascade of downstream cellular changes (7, 8). The receptors are glycoproteins, and their distribution across tissues is what determines where VIP exerts its effects: high VPAC1 density on certain cancer cell lines, for example, has driven research interest in VIP receptors as both targets for tumor imaging (using radiolabeled VIP analogues) and as potential therapeutic handles (4).
Receptor dynamics are themselves complex. After binding VIP, the receptor is internalized into the cell, the peptide is degraded in lysosomes, and the receptor is recycled back to the cell surface (8). There also appears to be an intracellular pool of unoccupied receptors that can be mobilized to the surface — a feature that may explain how cells maintain VIP responsiveness despite continuous signaling (8). Understanding this receptor biology has been central to designing both VIP agonists (to mimic its protective effects) and antagonists like VIPhybrid (used experimentally to block VIP-driven proliferation in certain cancer cell lines) (4).
Reported side effects from VIP in the published research are limited, in part because native VIP is rapidly degraded in circulation and has a very short half-life — under a few minutes — which constrains how it has been studied. The receptor biology is complex and context-dependent: VIP's effects vary substantially based on which receptors are present, the surrounding cytokine environment, and the activation state of target cells, meaning responses can differ across tissues.
The body of VIP evidence comes primarily from preclinical and laboratory work, with limited human clinical data so far. Long-term safety in humans has not been formally characterized. Researchers have noted that VIP receptors are present at high density on certain cancer cell lines and that VIP can stimulate proliferation in some of those models, which is relevant context for anyone evaluating the peptide's overall profile.
All information on this site is for research and educational purposes only. The compounds discussed are not approved by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.